Uterine cancer patients most commonly had alterations in TP53 (N = 18, 48.6%), PIK3CA (N = 7, 18.9%), KRAS (N = 5, 13.5%), ARID1A (N = 3, 8.1%), and PTEN (N = 3, 8.1%; Fig. 2C). This evidence concerns the gene PIK3CA and uterine cancer.